文献速递心力衰竭与心肌病血脂与心血管预防

心力衰竭通过循环因子刺激肿瘤生长

Heart Failure Stimulates Tumor Growth by Circulating Factors.
PubMed 文献 · Circulation · 2018-01-01

该研究利用APCmin小鼠和异位心脏移植模型发现,衰竭心脏可显著增加肠道肿瘤负荷(2.4倍,P<0.0001),且与左室功能障碍和纤维瘢痕严重程度相关。在人类中,慢性心衰患者血浆中serpinA3等蛋白升高,serpinA3可促进结肠癌细胞增殖;大型前瞻性队列显示心脏和炎症生物标志物升高可独立预测新发癌症。结论提示心衰可能是新发癌症的危险因素。

要点

  • 衰竭心脏通过循环分泌因子促进肿瘤生长,不依赖血流动力学障碍。
  • serpinA3等心脏分泌蛋白在慢性心衰患者血浆中升高,并可促进结肠癌细胞增殖。
  • 心脏和炎症生物标志物升高可独立于年龄、吸烟、BMI预测新发癌症。

核心结论

  • 心衰与肿瘤生长增强相关,且不依赖血流动力学障碍,可能由心脏分泌因子介导。
  • 心衰诊断可被视为新发癌症的危险因素。

研究设计与样本

  • 使用易发肠道癌前肿瘤的APCmin小鼠,通过大面积前壁心肌梗死诱导心衰并测量肿瘤生长。
  • 采用异位心脏移植模型(移植梗死或假手术心脏,保留原位心脏)排除血流动力学影响,6周后量化肿瘤数量、体积和增殖。
  • 在人类中测量候选分泌蛋白血浆水平(慢性心衰患者n=101,健康者n=180),并验证其对HT-29结肠癌细胞的增殖效应。
  • 在大型前瞻性一般人群队列(n=8319)中分析心脏特异和炎症生物标志物与新发癌症(n=1124)的关联。

主要发现

  • 衰竭心脏(原位和异位移植)使APCmin小鼠肠道肿瘤负荷显著增加2.4倍(all P<0.0001)。
  • 左室功能障碍严重程度和纤维瘢痕与肿瘤生长显著相关(P=0.002和P=0.016)。
  • 慢性心衰患者血浆中serpinA3、serpinA1、纤连蛋白、铜蓝蛋白和对氧磷酶1等蛋白较健康者升高(P<0.001)。
  • serpinA3对人结肠癌HT-29细胞产生显著增殖效应,伴Akt-S6磷酸化。
  • 看似健康人群中心脏和炎症生物标志物升高可独立于癌症危险因素(年龄、吸烟状态、BMI)预测新发癌症(n=1124)。

关键数值与推荐

  • APCmin小鼠中衰竭心脏导致肠道肿瘤负荷增加2.4倍(all P<0.0001)。
  • 左室功能障碍严重程度与肿瘤生长相关P=0.002,纤维瘢痕与肿瘤生长相关P=0.016。
  • 慢性心衰患者(n=101)较健康者(n=180)血浆serpinA3等蛋白升高P<0.001。
  • 一般人群队列n=8319中新发癌症n=1124,心脏和炎症生物标志物升高可独立预测新发癌症。

临床怎么用

  • 心衰患者应被视为新发癌症的高危人群,可能需要加强癌症筛查意识。
  • 心脏分泌因子(如serpinA3)可能成为心衰相关肿瘤风险的生物标志物或干预靶点。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Heart failure (HF) survival has improved, and nowadays, many patients with HF die of noncardiac causes, including cancer. Our aim was to investigate whether a causal relationship exists between HF and the development of cancer. METHODS: HF was induced by inflicting large anterior myocardial infarction in APCmin mice, which are prone to developing precancerous intestinal tumors, and tumor growth was measured. In addition, to rule out hemodynamic impairment, a heterotopic heart transplantation model was used in which an infarcted or sham-operated heart was transplanted into a recipient mouse while the native heart was left in situ. After 6 weeks, tumor number, volume, and proliferation were quantified. Candidate secreted proteins were selected because they were previously associated both with (colon) tumor growth and with myocardial production in post-myocardial infarction proteomic studies. Myocardial gene expression levels of these selected candidates were analyzed, as well as their proliferative effects on HT-29 (colon cancer) cells. We validated these candidates by measuring them in plasma of healthy subjects and patients with HF. Finally, we associated the relation between cardiac specific and inflammatory biomarkers and new-onset cancer in a large, prospective general population cohort. RESULTS: The presence of failing hearts, both native and heterotopically transplanted, resulted in significantly increased intestinal tumor load of 2.4-fold in APCmin mice (all P<0.0001). The severity of left ventricular dysfunction and fibrotic scar strongly correlated with tumor growth ( P=0.002 and P=0.016, respectively). We identified several proteins (including serpinA3 and A1, fibronectin, ceruloplasmin, and paraoxonase 1) that were elevated in human patients with chronic HF (n=101) compared with healthy subjects (n=180; P<0.001). Functionally, serpinA3 resulted in marked proliferation effects in human colon cancer (HT-29) cells, associated with Akt-S6 phosphorylation. Finally, elevated cardiac and inflammation biomarkers in apparently healthy humans (n=8319) were predictive of new-onset cancer (n=1124) independently of risk factors for cancer (age, smoking status, and body mass index). CONCLUSIONS: We demonstrate that the presence of HF is associated with enhanced tumor growth and that this is independent of hemodynamic impairment and could be caused by cardiac excreted factors. A diagnosis of HF may therefore be considered a risk factor for incident cancer.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Meijers WC, Maglione M, Bakker SJL, et al. Heart Failure Stimulates Tumor Growth by Circulating Factors. Circulation. 2018. PMID: 29459363. doi:10.1161/CIRCULATIONAHA.117.030816

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。